BR112015027569A2 - compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß - Google Patents

compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß

Info

Publication number
BR112015027569A2
BR112015027569A2 BR112015027569A BR112015027569A BR112015027569A2 BR 112015027569 A2 BR112015027569 A2 BR 112015027569A2 BR 112015027569 A BR112015027569 A BR 112015027569A BR 112015027569 A BR112015027569 A BR 112015027569A BR 112015027569 A2 BR112015027569 A2 BR 112015027569A2
Authority
BR
Brazil
Prior art keywords
tgf
compounds
compositions
activity
methods
Prior art date
Application number
BR112015027569A
Other languages
English (en)
Inventor
E Murphy-Ullrich Joanne
J Suto Mark
Original Assignee
Southern Res Inst
Uab Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst, Uab Res Found filed Critical Southern Res Inst
Publication of BR112015027569A2 publication Critical patent/BR112015027569A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

“compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-?” resumo a presente descrição refere-se a compostos, composições e métodos para o tratamento de doenças por meio da inibição da atividade do fator de transformação do crescimento beta (tgf-?). mais especificamente, os compostos descritos, composições e métodos são úteis no tratamento de certos tipos de câncer (por exemplo, mieloma múltiplo, neoplasias hematológicas), de doenças associadas com a atividade de tgf-? excessiva incluindo fibrose, cicatriz dérmica, disfunção imune, e perda de massa óssea por meio da inibição da conversão de tgf-? latente de tgf-? ativo. um método para prevenir a ativação de tgf-? na patologia é também fornecido, que compreende a administração de uma quantidade de compostos suficiente para inibir a conversão de tgf-? latente para tgf-? ativo por trombospondina 1 (tsp1), resultando em redução de tgf-? atividade e reduzidos efeitos adversos, tais como fibrose, perda de osso e disfunção imune. 1/1
BR112015027569A 2013-05-10 2014-05-09 compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß BR112015027569A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361822008P 2013-05-10 2013-05-10
PCT/US2014/037471 WO2014183018A2 (en) 2013-05-10 2014-05-09 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES THROUGH INHIBITING TGF-β ACTIVITY

Publications (1)

Publication Number Publication Date
BR112015027569A2 true BR112015027569A2 (pt) 2017-09-19

Family

ID=51865224

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027569A BR112015027569A2 (pt) 2013-05-10 2014-05-09 compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß

Country Status (10)

Country Link
US (1) US9353149B2 (pt)
EP (1) EP2994156A4 (pt)
JP (1) JP2016520069A (pt)
CN (1) CN105658229A (pt)
AU (1) AU2014262517B2 (pt)
BR (1) BR112015027569A2 (pt)
CA (1) CA2910196A1 (pt)
EA (1) EA201591623A1 (pt)
MX (1) MX2015014704A (pt)
WO (1) WO2014183018A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111655260A (zh) * 2017-10-26 2020-09-11 南方研究院 作为TGF-β抑制剂的噁二唑和噻二唑
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
WO2021195183A1 (en) * 2020-03-24 2021-09-30 Exo Therapeutics, Inc. Compositions and methods for inhibiting protein embryonic ectoderm development activity and treating disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09505555A (ja) * 1993-08-13 1997-06-03 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＴＧＦ−βの活性を刺激および阻害する方法および組成物
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
AU2001265082A1 (en) * 2000-05-26 2001-12-11 Beth Israel Deaconess Medical Center Thrombospondin-1 type 1 repeat polypeptides
DE10106852A1 (de) * 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
WO2007087738A1 (de) * 2006-02-03 2007-08-09 Pentapharm Ag Biologisch aktive tripeptide, deren kupferkomplexe und salze
CN101525373A (zh) * 2007-03-08 2009-09-09 独立行政法人理化学研究所 TGF-β活化反应阻碍物质
DE102008054117A1 (de) * 2008-10-31 2010-05-06 Henkel Ag & Co. Kgaa Wirkstoffkombination zur Behandlung reifer Haut II
CA2750559A1 (en) * 2009-02-05 2010-08-12 Digna Biotech, S.L. Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides
ES2347627B1 (es) * 2009-03-06 2011-10-10 Isdin, S.A. Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales.
WO2011159685A2 (en) * 2010-06-16 2011-12-22 The Regents Of The University Of Michigan Inhibition of wdr5 interaction with its binding partners and therapeutic methods
WO2012129237A2 (en) * 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd

Also Published As

Publication number Publication date
JP2016520069A (ja) 2016-07-11
WO2014183018A3 (en) 2015-01-22
AU2014262517B2 (en) 2018-10-18
EA201591623A1 (ru) 2016-05-31
AU2014262517A1 (en) 2015-11-12
CN105658229A (zh) 2016-06-08
WO2014183018A2 (en) 2014-11-13
CA2910196A1 (en) 2014-11-13
US9353149B2 (en) 2016-05-31
US20140336115A1 (en) 2014-11-13
EP2994156A2 (en) 2016-03-16
MX2015014704A (es) 2017-02-28
EP2994156A4 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
MX2020000404A (es) Inhibidores de tirosina quinasa de bazo (syk).
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
UY36207A (es) Inhibidores de la syk
BR112015022483A2 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
CU20130069A7 (es) Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
BR112015023448A2 (pt) compostos e composições para o tratamento de doenças parasíticas
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
SV2016005153A (es) Compuestos y composiciones como inhibidores de la mek
MX2015003021A (es) Derivados de acido glicirretinico y metodos de uso de los mismos.
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
MY179605A (en) Use of benzimidazole-proline derivatives
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
MX2020009738A (es) Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]
B12F Other appeals [chapter 12.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2660 DE 28/12/2021.